- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02322203
Effects of Niacin Therapy on Lipoprotein Composition and Function
Evaluation of the Effects of Niacin Therapy on Lipoprotein Composition and Function
Background:
- Niacin is a vitamin in many foods, including meats, fish, fruits, and vegetables. It is often used as a dietary supplement that causes many improvements in the body. Researchers think it can affect heart health.
Objective:
- To better understand the good effects of niacin supplementation on cholesterol, fat metabolism, and vascular health.
Eligibility:
- Adults 18 years of age and older with fasting good cholesterol (HDL-C) below 60 mg/dL.
Design:
- Participants will come to the clinic 4 times during the study.
- They will complete a 7-day food journal before visits 1 and 3.
- At visit 1, participants will be screened with questions about their diet and exercise, medical history, and any drugs and vitamins they take. Vital signs and body mass index will be measured.
- They will have a Cardio-Ankle Vascular Index (CAVI) test of the arteries. Blood pressure will be taken in the arms and legs and the heart will be monitored.
- Blood will be drawn. Participants will fast for 8 12 hours before this.
- Women will have a pregnancy test.
- Eligible participants will get a 2-week supply of niacin. They will take 2 tablets daily for one week, then 4 daily.
- Visit 2 will be 2 weeks after visit 1 and the niacin dose will be increased. Visit 3 will be 16 weeks after visit 1, and participants will stop taking niacin. Visit 4 will be 4 6 weeks after stopping niacin.
- During study visits, participants will repeat visit 1 tests.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
- Males and females who are at least 18 years of age at time of enrollment.
- Subject understands the investigational nature of the study and provides written, informed consent.
EXCLUSION CRITERIA:
- Subjects taking any lipid modification therapy, including but not limited to statins, fibrates and bile acid sequestrants.
- Subjects taking fish oil or any other supplements, which in the investigator s opinion may interfere with the study.
- Subjects with acute liver disease or active peptic ulcer disease.
- Subjects with elevated uric acid levels greater than 10 mg/dL or gout
- Pregnancy or women currently breastfeeding.
- Female subjects taking hormonal contraceptives or hormone replacement therapy may be included in this study only if they have been on a stable dose for at least 3 months.
- BMI less than 18.5
- Subjects with weight that varies greater than 20% over the past 3 months.
- Subjects taking the following medications for at least six weeks, which may interfere with the study, will be excluded: BAS, antibiotics, anticoagulants, anticonvulsants, antiarrhythmic, Cyclosporine, Mycophenolate and Synthroid. Subjects with chronic diarrhea, gastric bypass or lap band procedures, ostomies, bowel motility problems, or other conditions that could affect intestinal fat absorption.
- Subjects initiating new medications or patients on multiple medications may also be excluded.
- Inability to swallow capsules
- Patients with a history of type I or type II diabetes or HbA1c greater than 6.5%.
- Volunteers may also be excluded, if in the opinion of the study investigators, they have some other condition or disorder that may adversely affect the outcome of the study or the safety of the volunteer.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Niacin ER in healthy participants and its effects on lipoprotein composition and function
Niacin extended release (ER) to be given as follows: 500 mg/day for 1 week, then 1000 mg/day for 1 week, then 2000 mg/day for 14 weeks in healthy participants.
|
Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days.
Subjects will then be escalated to 2000 mg/day for 14 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in protein or lipid composition of any lipoprotein fraction and changes in vascular compliance as measured by CAVI
Time Frame: Ongoing
|
The primary outcome measurements of this study are changes in protein or lipid composition of any lipoprotein fraction and changes invascular compliance as measured by CAVI.
|
Ongoing
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marcelo J Amar, M.D., National Heart, Lung, and Blood Institute (NHLBI)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 150042
- 15-H-0042
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
National Human Genome Research Institute (NHGRI)Active, not recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
Clinical Trials on Niacin Extended Release
-
University of PennsylvaniaCompletedHealthy VolunteersUnited States
-
Hangzhou Highlightll Pharmaceutical Co., LtdCompleted
-
Cortria CorporationPPD; Pharmena North AmericaCompleted
-
Luye Pharma Group Ltd.Shandong Luye Pharmaceutical Co., Ltd.Completed
-
AstraZenecaWithdrawnHealthy Male Subjects | Pharmacokinetics | Safety | Food EffectUnited Kingdom
-
University of LeipzigCompletedCoronary Disease | HypolipoproteinemiaGermany
-
Merck Sharp & Dohme LLCTerminated
-
University of HawaiiUnited States Department of DefenseCompletedHIV Infections | Dyslipidemia | Endothelial DysfunctionUnited States
-
George ThanassoulisJewish General Hospital; Laval University; Quebec Heart InstituteWithdrawnAortic Stenosis and Lipoprotein(a) LevelsCanada
-
North Texas Veterans Healthcare SystemNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...CompletedAortocoronary Saphenous Vein Bypass Graft Atherosclerosis | Intermediate Saphenous Vein Graft LesionsUnited States